Achieving transplant tolerance remains the ultimate goal in the field of organ transplantation. We demonstrated previously that ablation of the transcription factor interferon regulatory factor 4 (IRF4) in T cells induced heart transplant acceptance by driving allogeneic CD4 + T cell dysfunction. Herein, we showed that hearttransplanted mice with T cell-specific IRF4 deletion were tolerant to donor-specific antigens and accepted the subsequently transplanted donor-type but not third-party skin allografts. Moreover, despite the rejection of the primary heart grafts in T cellspecific Irf4 knockout mice under immune checkpoint blockade, the establishment of donor-specific tolerance in these mice was unhindered. By tracking alloantigenspecific CD4 + T cells in vivo, we revealed that checkpoint blockade restored the expression levels of the majority of wild-type T cell-expressed genes in Irf4-deficient T cells on day 6 post-heart grafting, indicating the initial reinvigoration of Irf4-deficient T cells. Nevertheless, checkpoint blockade did not restore cell frequency, effector memory cell generation, and IFN-γ/TNF-α production of Irf4 −/− alloreactive T cells at day 30 post-heart grafting. Hence, targeting IRF4 represents a potential therapeutic strategy for driving intrinsic T cell dysfunction and achieving alloantigen-specific transplant tolerance.
| INTRODUC TI ON
Organ transplantation is a life-saving treatment for patients with end-stage organ failure, but long-term graft survival is limited by immune rejection and side effects of immunosuppressive drugs. 1 Allogeneic T cell response plays a decisive role in transplant rejection. The activation signals through T cell receptor (TCR), along with costimulation and cytokine inputs, mediate T cell response to organ transplants. [2] [3] [4] Hence, for more effective control of transplant immunity, it is essential to define the key regulators that link the TCR and other signals to the functional fates of alloreactive T cells.
Interferon regulatory factor 4 (IRF4) is a member of the IRF family of transcription factors. IRF4 is preferentially expressed in hematopoietic cells and plays critical roles in the differentiation and function of T cells, B cells and dendritic cells. [5] [6] [7] We found that IRF4 was promptly induced in T cells upon TCR signaling through the MEK1/2 pathway. IRF4 ablation in T cells resulted in progressive establishment of CD4 + T cell dysfunction and induced heart allograft acceptance in mice. The dysfunctional state of Irf4 −/− T cells was initially reversible by blocking programmed deathligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4
(CTLA-4), but it progressively developed into a terminal/irreversible dysfunctional state. 8 Therefore, the TCR-IRF4 axis governs the functional versus dysfunctional fates of alloreactive T cells.
Recent reports showed that in patients with stable function of transplanted kidneys but also developed metastatic cancer, programmed cell death protein 1 (PD-1) blockade was used to treat cancer. Unfortunately, PD-1 blockade triggered acute rejection of the transplanted kidneys. 9, 10 Therefore, irreversible dysfunction of alloreactive T cells was not established in those kidney recipients, though they were under chronic immunosuppression.
Low dose of FK506, the mainstay immunosuppressant, has even been shown to inhibit the terminal differentiation of T cell dysfunction. 11 Hence, in the context of achieving stable transplant tolerance, it would be essential to define the irreversible state of T cell dysfunction.
Herein, we investigated the irreversible dysfunctional state of 
| MATERIAL S AND ME THODS

| Mice
| Murine heterotopic heart transplantation
Hearts from BALB/c donors were transplanted into 8-10-week-old 
| Murine skin transplantation
BALB/c and C3H ear skin allografts were transplanted onto BALB/c heart transplanted Irf4 fl/fl Cd4-Cre mice by a previously described method. 12 More than 80% necrosis of the donor skin tissue was considered as rejection. IRF4-GFP or GFP-Ctrl retrovirus as previously described. 8 Cells were cultured for 1 day after transduction, and then adoptively transferred into Irf4 fl/fl Cd4-Cre mice on day 1 post-heart transplantation.
| Irf4 transduction and adoptive transfer of
| Adoptive transfer of TEa cells and microarray analysis
Microarray was performed by the Genomic and RNA Profiling Core BioLegend. Intracellular staining method was previously described. 
| Statistical analysis
Data were represented as mean ± SD and analyzed with Prism version 7.0a (GraphPad Software, San Diego, CA). The P values of skin graft survival were determined by the Mann-Whitney test. Other measurements were performed using unpaired Student's t test.
Differences were considered significant when P < .05.
| RE SULTS
| Ablation of IRF4 in T cells abrogates their ability to reject donor-type skin grafts in heart transplanted recipients
We have previously shown that alloreactive T cell dysfunction was achieved in Irf4 fl/fl Cd4-Cre mice after heart transplantation. 8 To determine whether induced T cell dysfunction affects the survival of subsequently transplanted skin allografts, Irf4 mAbs on days 0, 3, and 5 post-heart grafting. All heart allografts were acutely rejected within 8 days as previously described. 8 Recipients with rejected heart allografts were then transplanted again with skin allografts 30 days after heart grafting. Strikingly, all BALB/c skins were accepted on those recipients (MST of >100 days; n = 6), while all C3H skins were rejected within 60 days (MST = 47.0 ± 9.67 days; n = 6) ( Figure 3) . Therefore, checkpoint blockade induced acute heart transplant rejection in Irf4 fl/fl Cd4-Cre recipients, but did not prevent the later establishment of transplant tolerance.
F I G U R E 3
Checkpoint blockade does not prevent the establishment of transplant tolerance in Irf4-deficient mice. Irf4 fl/fl Cd4-Cre mice were transplanted with BALB/c hearts on day 0 and treated with anti-PD-L1 and anti-CTLA-4 (αPD-L1 + αCTLA-4) mAbs on days 0, 3, and 5 to trigger heart graft rejection. Recipients with rejected heart allografts were then transplanted again with BALB/c and C3H skin allografts 30 days after heart grafting (n = 6). A, Schematic of the experimental design. B, The percentage of skin allograft survival after skin transplantation on αPD-L1 + αCTLA-4 treated, BALB/c heart graft rejected Irf4 fl/fl Cd4-Cre mice. **P = .0022;
Mann-Whitney test. C, Representative images of accepted BALB/c skin allografts (>100 days) on αPD-L1 + αCTLA-4 treated, BALB/c heart graft rejected Irf4 
| D ISCUSS I ON
Sixty-five years ago, Medawar et al demonstrated that mice injected at birth with allogeneic cells were subsequently able to accept skin allografts from the same donor strain. 15 Since then transplant tolerance was further achieved in adult animals through various approaches. 16, 17 Deletion, anergy, and Treg suppression of alloreactive T cells contribute to transplant tolerance. [18] [19] [20] [21] We have previously shown that ablation of IRF4 induced allogeneic T cell dysfunction. 8 Loss of IRF4 expression has also been shown to be associated with has been shown to be down-regulated on exhausted CD8 + T Cells, rendering them unresponsive to inflammatory cytokines. 23 IL-1R2 is a negative regulator of IL-1 signaling, 24 whereas Wnt signaling is essential for T cell memory. 25 It remains to be determined the role of these un-restored genes in establishing the irreversible state of
It is a challenge to determine whether transplant tolerance has been achieved in the clinic, and how to proceed if it has not.
Successful weaning from immunosuppression may be an indication of transplant tolerance, but it remains unclear how to stratify transplant recipients according to their likelihood of being able to discontinue immunosuppression. Moreover, transplant tolerance can be achieved and maintained after rejection, as demonstrated in murine and larger animal models. [26] [27] [28] [29] [30] Hence, there is a fundamental need to reveal the determinants of T cell fate in transplant tolerance. The current works identified IRF4 as a key determinant governing transplant tolerance, which will advance the understanding and further characterization of tolerogenic T cell fate.
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